Laura Lindsey, MD
Family Medicine · Muscle Shoals, ALNPI 1063520278
Payments from drug & device makers
Across 338 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$755
- AbbVie$394
- Pfizer$298
- AstraZeneca$272
- Bayer$237
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,052100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 80 | $1,450 |
| Lilly USA, LLC | 58 | $755 |
| AbbVie | 37 | $394 |
| Pfizer | 15 | $298 |
| AstraZeneca | 18 | $272 |
| Bayer | 15 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $201 |
| Johnson & Johnson | 15 | $196 |
| Amarin Pharma, Inc. | 11 | $169 |
| GSK | 14 | $165 |
| Astellas Pharma US Inc | 7 | $106 |
| Merck | 7 | $90 |
| Ironwood Pharmaceuticals, Inc | 6 | $86 |
| Boehringer Ingelheim | 4 | $65 |
| Dexcom, Inc. | 4 | $63 |
| Amgen(2 entities) | 5 | $62 |
| Ardelyx, Inc. | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Genentech USA, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Shield Therapeutics Inc | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Corcept Therapeutics | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Abbott | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,064 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $81,436 |
| FarxigaDapagliflozin Propanediol | 49 | $64,554 |
| TrulicityDulaglutide | 38 | $62,238 |
| JanuviaSitagliptin Phosphate | 40 | $59,230 |
| JardianceEmpagliflozin | 51 | $57,172 |
| MounjaroTirzepatide | 32 | $43,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $40,885 |
| EliquisApixaban | 26 | $30,962 |
| LinzessLinaclotide | 27 | $27,324 |
| MyrbetriqMirabegron | 13 | $13,227 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $12,284 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,894 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,281 |
| Atorvastatin Calcium | 328 | $3,578 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $3,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $755 | $106,03270 claims |
| Novo NordiskOzempic | $1,450 | $81,43658 claims |
| MerckJanuvia, Janumet Xr | $90 | $71,51452 claims |
| AstraZenecaFarxiga, Symbicort | $272 | $68,83561 claims |
| Boehringer IngelheimJardiance | $65 | $57,17251 claims |
| GSKTrelegy Ellipta | $165 | $40,88539 claims |
| PfizerEliquis | $298 | $30,96226 claims |
| AbbVieLinzess | $394 | $27,32427 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $13,22713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Muscle Shoals
- Terence HartMuscle Shoals$323K
- Jonathan ParkerMuscle Shoals$214K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.